IFP Advisors Inc Acquires 64,107 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

IFP Advisors Inc grew its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 31.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 271,132 shares of the biotechnology company’s stock after purchasing an additional 64,107 shares during the quarter. IFP Advisors Inc’s holdings in Aurinia Pharmaceuticals were worth $2,435,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Blue Trust Inc. grew its position in Aurinia Pharmaceuticals by 3,041.4% in the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 6,174 shares in the last quarter. FMR LLC grew its position in Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 3,919 shares in the last quarter. Union Bancaire Privee UBP SA bought a new stake in Aurinia Pharmaceuticals in the fourth quarter worth approximately $108,000. Atria Wealth Solutions Inc. bought a new stake in Aurinia Pharmaceuticals in the fourth quarter worth approximately $135,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Aurinia Pharmaceuticals by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company’s stock worth $202,000 after acquiring an additional 10,700 shares in the last quarter. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Price Performance

Shares of Aurinia Pharmaceuticals stock opened at $8.03 on Wednesday. The firm has a fifty day simple moving average of $8.27 and a 200-day simple moving average of $7.75. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 1-year low of $4.71 and a 1-year high of $10.67. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -53.53 and a beta of 1.22.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 19th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.